Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

Inclusion Criteria: * Age: between 19 and 40 years old. * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * Written informed consent obtained from the subjects Exclusion Criteria: * Positive titres at screening for anti-hepatitis antibodies. * Elevated serum liver enzymes. * History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. * Any acute disease at the moment of entry. * Chronic alcohol consumption. * Hepatomegaly, right upper quadrant abdominal pain or tenderness. * Any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study. * History of allergic disease likely to be stimulated by any component of the vaccine. * Simultaneous participation in any other clinical trial. * Previous vaccination with a hepatitis B vaccine. * Previous vaccination with an MPL containing vaccine. * Administration of immunoglobulins in the past 3 months and during the whole study period * Vaccination one month before and one month after each dose of the study vaccine